Examining how psychotherapy affects paranoia in schizophrenia
Official title: Testing the Role of Belief Updating in Persecutory Delusions
Run by Vanderbilt University Medical Center · NCT06835556 · Data updated 2026-11-12
This study is testing whether psychotherapy can help people with schizophrenia feel less paranoid and change how they think about their surroundings.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Vanderbilt University Medical Center Academic / other |
| Locations | 1 site (Nashville, Tennessee) |
| Status | Recruiting |
| Started | January 15, 2025 |
| Main results expected | September 3, 2029 |
| Study ends | February 1, 2030 |
| Registry record updated | September 30, 2026 |
| Trial ID | NCT06835556 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include men and women aged 18 to 65 with a diagnosis of a non-affective psychotic disorder and persistent persecutory delusions.
✕Probably not a fit
Patients with serious medical or neurological illnesses that interfere with cognitive functioning may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effects of psychotherapy on individuals with schizophrenia-spectrum disorders, specifically focusing on changes in belief updating and environmental volatility related to persecutory delusions. Participants will receive either Cognitive Behavioral Therapy for psychosis (CBTp) or treatment as usual (TAU) along with phone check-ins over a 16-week period. Assessments will be conducted at four different time points over six months, and MRI scans may be performed to observe corresponding brain activity changes. The study aims to determine if effective treatment can reduce prior expectations about environmental volatility and alter brain activity.
Why it matters
Potential benefit: If successful, this study could lead to improved therapeutic strategies for managing paranoia in patients with schizophrenia.
How similar studies have gone: Previous studies have shown promise in using psychotherapy to address delusions in schizophrenia, suggesting potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women age 18 - 65. * Communicative in English. * Premorbid IQ \>79 (WTAR) * Provide voluntary, written informed consent. * Stable medication regimen over at least the past two weeks, including the use of either an oral or intramuscular administration of an antipsychotic medication. * Diagnosis of a non-affective psychotic disorder (e.g. schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder) * A persecutory delusion scoring at least a 3 on the conviction scale of the Psychotic Symptoms Rating Scale (PSYRATS) that had persisted for at least two months and that was not considered the direct result of substance use. Exclusion Criteria: * Serious medical or neurological illness known to interfere with cognitive functioning (uncontrolled/unstable diabetes, uncontrolled hypothyroidism, Cushing's disease, Lupus, any demyelinating disease such as Multiple Sclerosis, HIV infection, CNS infection, unstable heart disease, active hepatitis, other significant endocrine condition, any cancer involving the CNS/brain, any uncorrected vision problems, tardive dyskinesia). * History of severe head trauma with loss of consciousness \>30 minutes. * Primary diagnosis of alcohol or substance use disorder or personality disorder
Where it's running
-
Vanderbilt University Medical Center
Nashville, Tennessee, United States Recruiting
Study contacts
- Study coordinator: Julia Sheffield, PhD
- Email: julia.sheffield@vumc.org
- Phone: 615-343-3839
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Transition Support for First-Episode Psychosis
A team-based program helps people experiencing their first psychotic episode move from hospital to outpatient care to see if they stay engaged and feel better.
-
SEEG-guided DBS for Schizophrenia
This study tests whether SEEG-guided deep brain stimulation can help people with treatment-resistant schizophrenia see if symptoms improve.
-
Using an epigenetic drug to boost virtual reality cognitive training for middle-aged and older adults with depression or bipolar disorder
This trial will test whether daily sodium butyrate combined with three weeks of virtual reality cognitive training improves thinking skills in symptomatically stable adults aged 40–75 with depression or bipolar disorder.
-
Medical and psychiatric profiling of adults admitted to general adult psychiatry wards
This project will collect questionnaires, rating scales, and case-note information from adults admitted to general adult psychiatry wards to see what their physical and mental health profiles look like.
-
iTEST: a blended mobile program to improve introspective accuracy (accurate self-judgment of abilities)
This trial tests whether iTEST — daily mobile cognitive training plus coaching that focuses on accurate self-judgment — helps adults with schizophrenia-spectrum or other psychotic disorders improve community functioning.
-
VR avatar therapy for psychosis: linking thinking, self-awareness, and social cognition
This project will test whether cognitive, metacognitive, and social-cognition factors relate to how well VR-based avatar therapy helps people with schizophrenia who have persistent auditory hallucinations.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.